First U.S. ANDA submission expands integrated development
Connecting API knowledge with finished-dose development and regulatory filing.
news updates
Q1 FY27: commercial execution and record quarterly results
Revenue of INR 5,753 million and EBITDA of INR 877 million reported for Q1 FY27.
Masulkhana inspection completed with NIL Form 483
Company reports its fourth consecutive NIL 483 inspection outcome.